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High throughput screening has signi￿ cantly contributed to advances
in drug discovery. The great increase in the number of samples
screened has been accompanied by increases in costs and in the data
required for the investigated compounds. High throughput pro￿ ling
addresses the issues of compound selectivity and speci￿ city. It
combines conventional screening with data mining technologies to
give a full set of data, enabling development candidates to be more
fully compared.
Introduction
With the development of high throughput screening
(HTS) during the past two decades, new technologies
have gained access to chemistry and biology laboratories.
The use of both laboratory robotics and automated
workstations has greatly increased the number of chemi-
cal entities that are synthesized for and tested against new
targets. While a decade ago a daily throughput of about
1000 compounds was considered suµ cient, nowadays
screening laboratories aim to achieve 100 times as many
samples in the same time. Combinatorial chemistry has
increased the daily output comparably and HTS has
become an important success factor for early lead ® nding.
Nearly all drug discovery research projects in the phar-
maceutical industry employ HTS screening assays as
initial steps to discover the chemical leads. These com-
pounds provide the structural basis for further medicinal
chemistry activities that focus on optimization of the lead
compounds with respect to the activity and selectivity
pro® le in order to identify the development candidate.
The pace of this technological development not only has
created bene® ts such as shortening the time required for
lead identi® cation but also has generated other consider-
able issues. Among these are the extensive cost increases
with the increased number of samples investigated. Assay
miniaturization and related developments have helped to
reduce the impact. The number of chemical entities that
enter the primary screening and the resultant number of
hits that require further evaluation have questioned the
hit selection and pro® ling. HTS, with a hit rate of
between 0.01 and 1%, depending on the target and test
concentration used, produces several hundred primary
hits while previously only a handful of suitable candi-
dates were available. The decision as to which candidate
to follow has a direct impact on the success rate during
the further development phase. The generation of pri-
mary hits and the selection of leads based on just their
structural properties does not predict the probability of
converting the lead into a drug. The drop-out rate during
development is still considerable and is associated with
high ® nancial losses in the pharmaceutical industry. Only
one out of approximately ten potential drug candidates
entering phase I of development will ® nally reach the
market. Insuµ cient pharmacological and pharmaceuti-
cal properties represent the majority of reasons for failure
[1]. Information on the compound properties relevant for
development is often incomplete with respect to data on
selectivity, solubility, pharmacokinetics and toxicology,
at the time when it is needed for decision making, since
such data are gathered sequentially.
High throughput pro￿ ling
With these speci® c issues in mind CEREP has built
recently an integrated drug discovery platform in order
to serve the changing and challenging needs in lead
® nding. The activities are based on the company’ s
strengths such as combinatorial chemistry, molecular
modelling and compound pro® ling. The starting point
of discovery programs is the utilization of diverse combi-
natorial libraries, such as Odyssey 5000, to initiate the
lead ® nding process. This library, constructed from more
than 1500 unique monomeric building blocks, was
designed to identify eµ ciently initial leads in a new
research program. The leads identi® ed are passed on to
the key component of CEREP’ s platform, high through-
put pro® ling (® gure 1).
High throughout pro® ling consists of two major com-
ponents, one of which is the pharmacological pro® ling
that addresses the issues of compound selectivity and
speci® city. Selectivity is determined by testing on closely
related targets such as di¶ erent subtypes of the target
receptor (or ion channel), di¶ erent isozymes of the target
enzyme, or other mechanistically related targets. In most
cases it is desirable to have greater than ten-fold selectiv-
ity for the desired target.
The primary purpose of speci® city testing is to identify
` promiscuous’ compounds that interact with several un-
related targets. Such interactions can be indicative of in
vivo side e¶ ects or safety problems. For these reasons the
selection of assays in a speci® city panel is often tailored to
check for known undesirable interactions.
The current standard test panel consists of a variety of
receptors, channels, transporter systems and enzymes but
may be easily extended according to the scientist’ s needs.
The activity pattern obtained allows the scientist to
distinguish favourable and adverse drug properties with
respect to its biological activity. Table 1 gives an over-
view of the di¶ erent assay classes selected and the
number of targets in each of them.
Traditionally the pharmacological and pharmaceutical
criteria have been assessed in a sequential manner with
the major focus on the compound potency and selectivity.
Often there is a round of compound optimization
through medicinal chemistry between each step. Each
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http://www.tandf.co.uk/journals 171step has been used to rank a group of hits from primary
screening. As it has not been practical to advance all
compounds, the lowest ranked are generally dropped at
each step. As a consequence, after signi® cant time and
expense many compounds are found to have high po-
tency but display only poor speci® city or pharmaceutical
properties. The focus of the pharmaceutical pro® ling, as
performed presently, addresses issues of solution proper-
ties, metabolism, intestinal permeability, and safety.
Now it is becoming practical through the application of
HTS technologies to secondary assays to quickly and cost
e¶ ectively generate a full data set encompassing the
criteria above on each hit compound from primary
screening. The advantage of this parallel (as opposed to
sequential) approach is that key decisions are made with
a full awareness of the positive and negative attributes of
each compound or compound class.
An example of compound pro® ling is given in ® gure 2.
The comparison of the activity pattern of the drugs
investigated allows us to chose the preferred candidate
out of a list of other competitors. The broad spectrum of
information obtained is the basis for and represents the
® rst step towards a knowledge-based decision in the drug
discovery. The risk of taking a compound into develop-
ment can be calculated and costly failures of losing a drug
on its long way to an investigational new drug (IND)
may be reduced or even completely avoided.
Recently we have pro® led several hundred publicly
available drugs and more than 100000 data points
have been collected using this approach. This has been
made possible by a proprietary assay technology imple-
mented on Zymark robot systems. In addition to the
biological data sets, structural ® ngerprints were estab-
lished using software packages that represent the spatial
orientation and distance of pharmacophoric groups
within the molecules. Together with the biological results
they are stored in a database. The data acquired accord-
ingly represent a unique basis for data mining with
respect to both the clustering of compounds and biologi-
cal tests. With the increase in the information content, it
will be possible to group development candidates accord-
ing to their structure with compounds of known pro® le in
the database. With the increasing amount of information
acquired, certain predictions may be possible not only
with respect to the compound’ s activity and physico-
chemical pro® le but also with respect to its in vivo proper-
ties. Based on the knowledge obtained, the selection of a
drug candidate with an increased probability of passing
through development and reaching the IND ® ling may
be achieved.
Another approach to using the indicative potential of the
data collection is the development of focused libraries for
screening against new targets. Analysis of the biological
targets and the activity pattern of the drugs obtained in
pro® ling allows the design of a test set of compounds.
This may be either based on the selection of chemical
Figure 1. Within the discovery platform at CEREP high throughput organic synthesis and high throughput pro￿ ling are main features that
enable the scientist to identify the respective candidate based on a broad resource of biological results.
Table 1. Standard target pattern in high throughput pharmaco-
logical and pharmaceutical pro￿ ling. User-de￿ ned modi￿ cation
may be accommodated.
Target Number of assays
Pharmacological pro® ling
G protein coupled receptors 29
Ion channel coupled receptors 2
Transporters 3
Ion channels 4
Enzymes 9
Pharmaceutical pro® ling
Drug Metabolism 9
Intestinal permeability 3
Drug safety 10
Solution properties
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e.g. G protein-coupled receptors, kinases etc., or on lead
explosion by the selection of drugs with a comparable
pro® le obtained in pro® ling. The feedback of the results
to molecular modelling enables the scientist to follow a
more rational way of drug design that will help to reduce
the e¶ ort and time normally spent.
Conclusion
During the past decade high throughput screening and
ultra high throughput screening have signi® cantly con-
tributed to the advances in drug discovery. The increase
in associated research costs and the bottlenecks further
down the development have increased the demand for
alternative approaches. Among these approaches, high
throughput pro® ling combines both the conventional
screening strategy combined with data mining tech-
nologies that will foster drug discovery in the new
millennium.
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Figure 2. Activity pro￿ les of compounds against more than 100 di¶ erent targets. The gray scale coding represents the activity obtained in
each test, typically expressed as per cent activation or inhibition depending on the target.
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